

Contents

1	Genetics and Classification of Acute Myeloid Leukemia	1
	Alison R. Walker and Guido Marcucci	
2	The Use of “Omics” to Guide the Selection of Targeted Therapy	27
	Steven M. Kornblau	
Part I Apoptosis		
3	Roles of Apoptosis-Regulating Bcl-2 Family Genes in AML	47
	John C. Reed	
4	Bcl-2 Family: Translational Aspects	67
	Prithviraj Bose and Steven Grant	
5	IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia	95
	Bing Z. Carter and Michael Andreeff	
6	TP53 Mutations in Acute Myeloid Leukemia	123
	Ulrike Bacher, Claudia Haferlach, Vera Grossmann, Susanne Schnittger and Torsten Haferlach	
7	Targeting p53 Tumor Suppressor for AML Therapy	135
	Kojima Kensuke and Lyubomir T. Vassilev	
8	AML-Selective Apoptosis Induction by Rationally Designed Death Ligand Fusion Proteins	151
	Edwin Bremer and Wijnand Helfrich	

Part II Signaling

9 PIM Kinases in AML	177
Lisa S. Chen and Varsha Gandhi	
10 Development of Midostaurin as a Tyrosine Kinase Inhibitor	201
Gabriela Motyckova and Richard M. Stone	
11 FLT3 in AML	215
Naval Daver and Farhad Ravandi	
12 FLT3-ITD. Clinical (Sorafenib/AC220)	233
Naveen Pemmaraju and Jorge Eduardo Cortes	
13 Nucleophosmin (NPM1)	251
Ramesh Balusu, Warren Fiskus and Kapil N. Bhalla	
14 Raf/MEK/ERK Signaling	275
James A. McCubrey, Linda S. Steelman, Jörg Bäsecke and Alberto M. Martelli	
15 The Role of Translational Medicine in Optimization of Therapies Targeting the RAS-MAP Kinase Pathway	307
Judith S. Sebolt-Leopold	
16 Clinical Use of Farnesyltransferase Inhibitors	325
Chezi Ganzel and Jacob M. Rowe	
17 The PI3K-AKT-mTOR Signaling Network in AML	335
Brandon Beagle and David A. Fruman	
18 Targeting the PI3 Kinase-mTOR Signaling Pathway in AML	363
Martin Carroll	
19 Aurora Kinases	371
Subrata Sen and Hiroshi Katayama	
20 The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia	391
Kevin R. Kelly, Ciara L. Freeman and Francis J. Giles	

Part III Epigenetics

21 AML: Deacetylases	411
Margherita Ghisi and Ricky W. Johnstone	

22 Methylation in AML: Clinical Applications	441
Naveen Pemmaraju, Guillermo Garcia-Manero and Farhad Ravandi	

Part IV Nuclear Receptors

23 PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response	461
Hugues de Thé, Jun Zhu, Rihab Nasr, Julien Ablain and Valérie Lallemand-Breitenbach	

24 Arsenic Trioxide in Untreated APL	477
Elihu Estey	

25 Targeting PML-RARα with Retinoids	489
Eytan M. Stein and Martin S. Tallman	

26 NR4A Orphan Receptors as Drug Targets	509
Stephen Safe, Syng-Ook Lee, Cong Meng and Beiyan Zhou	

Part V Cell Surface Receptors

27 Antibody-Based Therapeutics Targeting CD33, CD45, and CD66	531
Roland B. Walter, Oliver W. Press and Irwin D. Bernstein	

Part VI Stem Cells

28 New Heterogeneity of the Leukemic Stem Cells	559
Dominique Bonnet	

29 Targeting Leukemia Stem Cells	573
Duane C. Hassane and Monica L. Guzman	

Part VII Microenvironment

30 Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling	593
Daniel C. Link	

31 CXCR4/CXCL12 as a Therapeutic Target	607
Geoffrey L. Uy and John F. DiPersio	

32 VLA-4: A Cell's Consequential Encounter	617
Thalia Papayannopoulou	

33 VLA-4 Function and Prognosis in Acute Myeloid Leukemia	627
Pamela S. Becker and Frederick R. Appelbaum	

34 VLA4 in Acute Lymphoblastic Leukemia..... 637
Halvard Bönig and Yong-Mi Kim

Part VIII Hypoxia

35 The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs 657
Juliana Benito, Marina Konopleva and William R. Wilson

Part IX Micro-RNAs

36 MicroRNAs as Therapeutic Targets..... 683
Maitri Y. Shah and George A. Calin

37 Clinical Implications of MicroRNAs in AML..... 699
Parvathi Ranganathan and Ramiro Garzon

Part X Metabolism

38 Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias..... 709
Rob C. Laister, Mark D. Minden and Tak W. Mak

39 Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells 725
Ismael Samudio and Juliana Vélez

Part XI Cell Therapy

40 NK-Cell Immunotherapy for AML 737
Dean Anthony Lee, Laurence James Neil Cooper and Elizabeth J. Shpall

41 Allogeneic and Autologous T-cell Strategies to Enhance Targeting of Acute Myeloid Leukemias 757
Gerrit Weber, Catherine M. Bollard and A. John Barrett

42 Indications for Hematopoietic Transplantation for AML..... 777
Sairah Ahmed and Richard Champlin

43 Mesenchymal Stem/Stromal Cell-Targeted Therapies for Solid Tumors and Hematological Malignancies 799
Christopher H. Booth, Lysette Mutkus, Karen Bussard, Erika Spaeth, Michael Andreeff and Frank C. Marini

Index..... 821



<http://www.springer.com/978-1-4939-1392-3>

Targeted Therapy of Acute Myeloid Leukemia

Andreeff, M. (Ed.)

2015, XIX, 826 p. 62 illus., 46 illus. in color., Hardcover

ISBN: 978-1-4939-1392-3